HC Wainwright set a $25.00 price target on Oramed Pharmaceuticals (NASDAQ:ORMP) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Separately, ValuEngine upgraded shares of Oramed Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, May 31st.
Shares of Oramed Pharmaceuticals opened at $7.74 on Wednesday, Marketbeat Ratings reports. Oramed Pharmaceuticals has a 12 month low of $6.15 and a 12 month high of $11.34.
An institutional investor recently bought a new position in Oramed Pharmaceuticals stock. Millennium Management LLC bought a new stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,849 shares of the biotechnology company’s stock, valued at approximately $143,000. Millennium Management LLC owned approximately 0.11% of Oramed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.91% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.